Flagship Pioneering

https://www.flagshippioneering.com

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by more than $3.3 billion of aggregate capital commitments, of which over $1.7 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 37 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics, Indigo Agriculture, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS). *

	Start	2016-12-15 renamed
	Predecessor	Flagship Ventures
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Afeyan, Noubar (Flagship Ventures 200603 managing partner + CEO)
	Person 2	Biondi, Paul (Flagship Pioneering 201912– Executive Partner before BMS 2002–2019 most recently SVP Strategy + BusDev)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	55 Cambridge Parkway Suite 800E
	City	02142 Cambridge, MA
	Tel	+1-617-868-1888
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	1,400,000,000 (capital under management 2015-05-05)

		* Document for »About Section«: Flagship Pioneering. (12/16/19). "Press Release: Flagship Pioneering Strengthens Leadership with Appointment of Paul Biondi as Executive Partner". Cambridge, MA.

		Record changed: 2024-01-07